Phosphatidylcholine: uses, evidence, dosing and safety

Phosphatidylcholine is one of the main phospholipids in cell membranes. It is also the main dietary source of choline, an essential nutrient that is naturally present in some foods and available as a dietary supplement. As a supplement it is sold, often as lecithin, for the liver, the brain and general wellness. A separate injectable version is marketed to dissolve fat. The honest picture is narrower than the marketing. The best evidence is in ulcerative colitis, a type of inflammatory bowel disease. Even there, the largest trials did not confirm the early promise. For memory and most other uses, the evidence is weak.

This is general information, not medical advice. Speak with a clinician before starting any supplement, especially if you take medication or are pregnant.

What it is

Phosphatidylcholine is a phospholipid, a type of fat molecule that forms the membranes around cells. The body needs choline to synthesize phosphatidylcholine and sphingomyelin, two major phospholipids vital for cell membranes. The Institute of Medicine established dietary reference intakes for choline in 1998, formally recognizing it as a nutrient the body needs from food. Choline and phosphatidylcholine are related, but not the same. Choline is a small nutrient. Phosphatidylcholine is a larger fat molecule that carries a choline group and releases choline when it is digested. About half the dietary choline consumed in the United States is in the form of phosphatidylcholine.

You get it from foods rich in choline. The main dietary sources are animal foods: meat, poultry, fish, dairy products and eggs. Beef liver and eggs are among the richest sources. Many foods also contain lecithin, a substance rich in phosphatidylcholine. Lecithin is usually made from soybeans or sunflower. The forms of choline in dietary supplements include choline bitartrate, phosphatidylcholine and lecithin. Two other popular choline supplements, citicoline and alpha-GPC, are different compounds, and the evidence below does not apply to them.

How it works

Much of what follows is about choline, the nutrient, because phosphatidylcholine’s main job is to deliver it. Where the evidence is about phosphatidylcholine itself, we say so.

Once you eat it, digestive enzymes free the choline it carries. The body then uses both the fat and the choline. Choline is a source of methyl groups needed for many steps in metabolism. Methyl groups are small chemical tags the body adds to molecules to switch processes on or off. Choline is also needed to produce acetylcholine, an important neurotransmitter for memory, mood and muscle control. A neurotransmitter is a chemical messenger that nerve cells use to signal one another. As a fat, it is a building block for cell membranes. Choline, especially phosphatidylcholine, is essential for transporting lipids, meaning fats, from the liver.

The body makes some phosphatidylcholine itself. It does this through what scientists call de novo synthesis of phosphatidylcholine, a build-from-scratch route that estrogen increases. In the liver this route is run by an enzyme called PEMT, and its gene expression is induced by estrogen. That may help explain why premenopausal women are relatively resistant to choline deficiency compared with postmenopausal women and men. When healthy volunteers were deprived of choline, about 44 percent of premenopausal women developed fatty liver or muscle damage, versus roughly 77 to 80 percent of men and postmenopausal women.

Genetics matter too. Common differences in the genes that handle choline influence the dietary requirement, so some people need more than others. In one experiment, most people carrying a particular variant of the PEMT gene developed organ dysfunction when fed a low-choline diet. Even so, the amount the body synthesizes on its own is not sufficient to meet human needs. In a classic experiment, healthy people fed a choline-free diet developed signs of incipient liver dysfunction, evidence that choline is an essential nutrient for humans.

What the evidence says

Most health claims for phosphatidylcholine are not equally supported. The table below grades the main uses, and the sections after it explain each one. Each grade reflects both how well a use has been tested and which way the evidence points.

Use	Evidence grade	What the research shows
Ulcerative colitis (add-on to standard care)	Weak; not confirmed by the largest trials	Early trials found phosphatidylcholine reduced corticosteroid dependence more than placebo, but the largest modified-release trials did not confirm the benefit: the induction trial was terminated early for futility and the maintenance trial matched placebo
Fatty liver disease	Preliminary, industry-funded	Essential phospholipids are used for fatty liver, but the data are mostly from small-scale studies
Alcohol-related liver disease	No benefit in the largest trial	In 789 heavy drinkers, polyenylphosphatidylcholine did not affect progression of liver fibrosis
Memory or thinking in healthy adults	Insufficient	Evidence from randomized trials does not support the use of lecithin for dementia
Heart health	A concern, not a benefit	Higher TMAO from gut bacteria is associated with an increased risk of heart problems, though the cause is debated
Injectable “fat-dissolving” phosphatidylcholine (a different product and route from the oral supplement)	Not approved and harmful	Unapproved fat-dissolving injections have caused permanent scars, serious infections and skin deformities

Ulcerative colitis: the strongest case, and its limits

The idea starts with the gut lining. The mucus layer that protects the colon is normally rich in phosphatidylcholine, and people with ulcerative colitis have less of it: patients with ulcerative colitis have significantly less phosphatidylcholine in their intestinal mucus than healthy people. An insufficient level of phosphatidylcholine in colonic mucus is a possible pathogenetic factor for ulcerative colitis. So researchers tested a special delayed-release form, made to reach the colon.

In one randomized trial at a German university hospital, 60 patients with chronic steroid-refractory ulcerative colitis took phosphatidylcholine or a placebo. Phosphatidylcholine reduced corticosteroid dependence more than placebo: 80 percent of the treated patients came off steroids without a flare, versus 10 percent on placebo; on the trial’s stricter primary measure, off steroids and disease under control, it was 50 percent versus 10 percent. An earlier trial in chronic active disease used a dose of 6 grams daily over three months. It reported that retarded-release oral phosphatidylcholine is effective in alleviating inflammatory activity caused by ulcerative colitis.

These early results were encouraging, but limited. The trials were small and short; the authors of the steroid-refractory trial noted the sample size was small, and the study was of short duration. They also came largely from one research group led by the same investigator, Wolfgang Stremmel. Later, the same group pooled three of its own single-center trials of a 30 percent phosphatidylcholine lecithin and reported it improved the rate of remission, while noting that a separate trial of a stronger, over 94 percent formula had failed. In other words, the positive and negative results come from an overlapping set of studies, which is why independent replication matters.

Then a larger, multi-center program tested a modified-release form as an add-on to standard mesalamine treatment, and the picture changed. The induction trial was stopped early for futility after 466 of a planned 762 patients had enrolled, meaning it was halted because it was not working. This came despite prior evidence of beneficial effects of phosphatidylcholine in phase 2 trials. A separate maintenance trial lasting about a year compared modified-release phosphatidylcholine against placebo and standard mesalamine. It found no advantage in remission rates at week 48: 49.3 percent stayed in remission on phosphatidylcholine, versus 43.2 percent on placebo and 50.0 percent on mesalamine. The authors said signals of efficacy require confirmation in an adequately powered maintenance trial. The treatment was safe, but it did not work at scale. The honest summary: a real biological rationale, promising small trials, and a benefit that did not hold up in the largest tests.

Fatty liver disease: preliminary, and worth reading closely

Phosphatidylcholine has long been sold for the liver. It is usually given as essential phospholipids, a soybean-derived phosphatidylcholine concentrate. Essential phospholipids are used for fatty liver, but the data are mostly from small-scale studies. Pooling those studies, one review found a benefit of essential phospholipids in patients with fatty liver who also had diabetes or obesity, and said further large-scale trials are warranted.

That review, however, was funded by Sanofi, and one of its two authors is an employee of Sanofi. That does not make it wrong, but it is worth knowing when weighing an industry-backed conclusion. It is also worth knowing that major liver guidelines do not list essential phospholipids among recommended treatments. The current guidance from the American Association for the Study of Liver Diseases notes there are no FDA-approved drugs for NASH, the inflammatory form of fatty liver disease, and points to options such as vitamin E and pioglitazone. For now the liver evidence is preliminary: suggestive, mostly from smaller studies, and not confirmed by large independent trials.

Alcohol-related liver disease: the biggest trial was negative

The picture is clearer for alcohol-related liver disease, and it is not encouraging. Polyenylphosphatidylcholine, a soybean form of phosphatidylcholine, had prevented alcoholic cirrhosis in animals. Cirrhosis is severe scarring of the liver. It was then put to the test at Veterans Affairs medical centers in 789 patients, who received the supplement or a placebo for two years. It did not affect progression of liver fibrosis, the scarring of the liver, and did not beat placebo on the main outcome. This is the largest phosphatidylcholine liver trial, and it found no benefit.

There is one setting where choline clearly helps the liver. In patients receiving parenteral nutrition, meaning feeding through a vein, choline deficiency contributes to TPN-associated liver disease, and a placebo-controlled trial found that adding choline reversed the liver abnormalities. This is a specific medical situation, not a reason for healthy people to supplement.

Memory and thinking: insufficient

Because it supplies choline, and choline helps make the memory messenger acetylcholine, phosphatidylcholine is often marketed for the brain. The reasoning is real; the results are not. Some experts have theorized that consuming higher levels of phosphatidylcholine could reduce the progression of dementia in people with Alzheimer’s disease. When that idea was tested, it did not hold up. A Cochrane review of lecithin, the phosphatidylcholine-rich supplement, found that evidence from randomized trials does not support the use of lecithin in the treatment of patients with dementia. The reviewers added that a moderate effect cannot be ruled out, but that review is now more than 20 years old and has not been updated. No good evidence shows it sharpens memory in healthy adults.

Heart health: no benefit, and a debated concern

No good evidence shows phosphatidylcholine helps the heart. There is a specific concern instead, and it is worth getting the biology right. Gut bacteria turn the choline in dietary choline and phosphatidylcholine into trimethylamine, or TMA; the liver enzyme FMO3, short for flavin-containing monooxygenase 3, then converts that into TMAO, short for trimethylamine N-oxide. So the gut bacteria make TMA, and the liver makes TMAO. In a study of thousands of adults having heart tests, higher levels of TMAO were associated with an increased risk of a major adverse cardiovascular event. That means a heart attack, stroke or death. The production of TMAO from dietary phosphatidylcholine depends on the gut bacteria.

But the story is not one-sided, and cause and effect are debated. First, the association does not rest on a single study. A later meta-analysis pooling 11 prospective cohort studies found higher circulating TMAO was associated with a higher risk of cardiovascular events. Second, the biggest dietary source of TMAO is oily fish, which is heart-healthy. Fish raises blood TMAO far more than eggs or beef, and already contains TMAO that can be absorbed without processing by gut microbes. Third, the genetics evidence points both ways. One genetics-based study found naturally higher TMAO was not linked to higher odds of heart disease or stroke. Instead, it suggested diabetes and kidney disease raise TMAO, so the link may reflect confounding or reverse causality. But a separate study reached the opposite conclusion: genetically higher phosphatidylcholine can increase the risk of a heart attack. So the causal question is genuinely unresolved. That makes TMAO a reason for caution about very high doses, not proof that phosphatidylcholine is safe, and not proof that it causes heart disease.

Other studied uses

Phosphatidylcholine and lecithin have been promoted for many other things. For most, the honest answer is that the evidence is thin or missing. They have been tried or marketed for gallstones, high cholesterol, skin conditions such as eczema, premenstrual symptoms, anxiety and mood, immune support and anti-aging, and lately for “detox” after mold exposure or long COVID. None of these has good supporting evidence in people. Some rest only on animal or test-tube work, and others have never been properly tested. Where a claim sounds specific, the specificity usually comes from the marketing, not from trials.

The injectable “fat-dissolving” version is a different, unapproved product

You may have seen phosphatidylcholine injected to dissolve fat, in treatments marketed as Lipodissolve, Aqualyx, mesotherapy or injection lipolysis. This is not the same as the oral supplement, and it is not approved. Common ingredients in these injections include phosphatidylcholine and sodium deoxycholate. The US Food and Drug Administration says these fat-dissolving injections are not approved, and it has received reports of adverse reactions such as permanent scars, serious infections, skin deformities, cysts, and deep, painful knots.

Laboratory work backs up the concern. When phosphatidylcholine mixed with deoxycholate was injected under the skin of rats and a human volunteer, it caused tissue fibrosis and necrosis of adipose and vascular tissues, meaning scarring and death of fat and blood-vessel tissue. Only one injectable fat-reducing drug is FDA approved: Kybella, the brand name for deoxycholic acid, cleared to reduce fat under the chin in adults, and it is a different molecule from phosphatidylcholine. The FDA warns that consumers should not purchase ingredients for these unapproved injections or inject the drugs themselves. If you are considering fat reduction, see a licensed provider about approved options.

Dosing and forms

There is no established therapeutic dose, and the research doses are not a recommendation. The ulcerative colitis trials used special delayed-release forms, so it would reach the colon. The steroid-refractory trial gave a total dosage of 2 grams a day. The chronic active trial used a dose of 6 grams daily over three months. Those research formulations are not the same as lecithin capsules sold in shops.

Ordinary supplements come as lecithin or purified phosphatidylcholine, in capsules, softgels or granules. How much actual phosphatidylcholine they contain varies a lot, because lecithin is a mixture of phospholipids, not pure phosphatidylcholine. So a label that says lecithin can mean very different amounts. Lecithin is sold as soy or sunflower; there is no evidence one form works better, so the choice is mainly about allergies and preference. There is no good evidence about the best time of day to take it, and taking it with food may help tolerability.

Phosphatidylcholine is also sold next to two other choline supplements, citicoline and alpha-GPC, but they are not the same molecule. Citicoline, also called CDP-choline, and alpha-GPC deliver choline in different chemical forms and are studied mainly for the brain. The evidence in this article is about phosphatidylcholine and does not carry over to them.

Safety, side effects and who should avoid

At the amounts found in food and typical supplements, phosphatidylcholine and lecithin are generally regarded as safe. In the colitis trials, mild bloating was a common side effect. The clearer limits come from choline, which phosphatidylcholine delivers. High intakes of choline are associated with a fishy body odor, vomiting, excessive sweating and salivation, hypotension, and liver toxicity. Hypotension means low blood pressure. So there is a ceiling. The tolerable upper intake level for choline for adults is 3,500 milligrams a day. For comparison, the adequate intake is 550 milligrams a day for men and 425 for women, the amount thought to cover daily needs. That limit is for healthy adults, not for people taking high doses of choline under medical supervision.

A few people should be especially careful. People with a rare inherited condition called trimethylaminuria, or fish odor syndrome, cannot properly clear trimethylamine because their FMO3 enzyme, short for flavin-containing monooxygenase 3, does not work as it should. For them, extra choline makes the problem worse, so they are told to limit choline-rich foods and supplements including fish oil and choline, and often fish and seafood as well, whose breakdown can make sweat and breath smell like rotten fish.

Kidney disease is another reason for caution. Because TMAO is cleared by the kidney, people with reduced kidney function tend to have higher levels, so anyone with kidney disease should talk to a clinician before taking choline or phosphatidylcholine supplements.

If you have a soy allergy, soy-derived lecithin is usually fine. Most of the protein is removed when it is made, and soy lecithin does not contain sufficient soy protein residues to provoke allergic reactions in the majority of soy-allergic consumers. Still, some of the more sensitive soybean-allergic consumers might react, so sunflower lecithin is an alternative.

Pregnancy and breastfeeding are a special case, and here the evidence is more encouraging, though it is about choline generally, not phosphatidylcholine specifically. The recommended choline intake rises: the adequate intake is 450 milligrams a day during pregnancy and 550 milligrams a day during lactation. Most people in the United States consume less than the adequate intake for choline, and choline is often missing from prenatal vitamins. In a tightly controlled feeding study that used a choline supplement, women in their third trimester took either 480 or 930 milligrams of choline a day, and the higher amount improved infant information processing speed, a measure of how quickly babies took in new information. So getting enough choline in pregnancy matters, but that is not a reason to take phosphatidylcholine specifically, and it is worth discussing with a clinician.

For most healthy people, deficiency is not the reason to supplement. Although most take in less than the recommended amount, frank choline deficiency in healthy people is very rare.

Interactions

Formal drug-interaction data are limited. The clearest interaction is indirect. Gut bacteria turn the choline in phosphatidylcholine into TMA, which the liver converts to TMAO. So anything that changes those bacteria, such as antibiotics, can change how much TMAO is made. In the heart study, plasma levels of TMAO were markedly suppressed after the administration of antibiotics, then returned once the antibiotics stopped.

There is also a theoretical caution with blood-pressure medicines. High intakes of choline are associated with hypotension, so taking large doses alongside blood-pressure medication could add to that blood-pressure-lowering effect. The data here are limited, which is another reason to involve a clinician rather than guess.

Bottom line

Phosphatidylcholine is a genuine and important molecule. That is not the same as a proven supplement. As a food component and a source of choline, it matters for everyone. Getting enough choline is a real issue in pregnancy. As a targeted treatment, its record is thin. The one area with real disease-specific evidence is ulcerative colitis. Even there, the encouraging early trials were not confirmed when a larger program put a modified-release form to the test. The non-alcoholic fatty liver evidence is preliminary. Separately, the largest trial, in people with alcohol-related liver disease, was negative. The idea that it sharpens memory is undercut by trials of lecithin.

If you have ulcerative colitis, it is worth discussing with a gastroenterologist, but as an experimental add-on to standard care, not a replacement. For general brain or heart health, the case is weak. The link to TMAO is a reason not to take large doses casually, even if its role in disease is still debated. The injectable fat-dissolving version is a separate, unapproved product with real harms, and it should not be confused with the supplement. As with any supplement, the sensible step is to talk to your doctor, especially if you are pregnant, take medication, or have a chronic condition such as kidney disease.